Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors

Pediatric Blood and Cancer

Volumn 59, Issue 7, 2012, Pages 1155-1157

  Kieran, Mark W ^a   Roberts, Charles W M ^a   Chi, Susan N ^a   Ligon, Keith L ^b,c   Rich, Benjamin E ^b,c   Macconaill, Laura E ^b   Garraway, Levi A ^b   Biegel, Jaclyn A ^d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AT RT; OncoMap; Rhabdoid; Targeted therapy

Indexed keywords

ARTICLE; CARCINOGENESIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DRUG TARGETING; FEMALE; GENE MUTATION; HUMAN; INFANT; MALE; MASS SPECTROMETRY; ONCOGENE; PRESCHOOL CHILD; PRIORITY JOURNAL; RHABDOID TUMOR; SCHOOL CHILD; TUMOR SUPPRESSOR GENE;

CHILD; CHILD, PRESCHOOL; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; FEMALE; GENES, TUMOR SUPPRESSOR; GENOTYPING TECHNIQUES; HUMANS; INFANT; MALE; MASS SPECTROMETRY; MUTATION; ONCOGENES; RHABDOID TUMOR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84867365943     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24315     Document Type: Article

References (25)

1. Roberts CW, Biegel JA. The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther 2009;8:412-416.
2. Hollmann TJ, Hornick JL. INI1-deficient tumors: Diagnostic features and molecular genetics. Am J Surg Pathol 2011;35:e47-e63.
3. Chi SN, Zimmerman MA, Yao X, et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 2009;27:385-389.
4. van den Heuvel-Eibrink MM, van Tinteren H, Rehorst H, et al. Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study group. Pediatr Blood Cancer 2011;56:733-737.
5. Bourdeaut F, Freneaux P, Thuille B, et al. hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. J Pathol 2007;211:323-330.
6. Eaton KW, Tooke LS, Wainwright LM, et al. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer 2011;56:7-15.
7. Jackson EM, Sievert AJ, GAi X, et al. Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors. Clin Cancer Res 2009;15:1923-1930.
8. McKenna ES, Sansam CG, Cho YJ, et al. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol Cell Biol 2008;28:6223-6233.
9. Birks DK, Donson AM, Patel RR, et al. High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival. Neuro Oncol 2011;13:1296-1307.
10. Bruggers CS, Bleyl SB, Pysher T, et al. Clinicopathologic comparison of familial versus sporadic atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system. Pediatr Blood Cancer 2011;56:1026-1031.
11. Wilson BG, Wang X, Shen X, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 2010;18:316-328.
12. Venneti S, Le P, Martinez D, et al. p16INK4A and p14ARF tumor suppressor pathways are deregulated in malignant rhabdoid tumors. J Neuropathol Exp Neurol 2011;70:596-609.
13. Nagata T, Takahashi Y, Ishii Y, et al. Molecular genetic alterations and gene expression profile of a malignant rhabdoid tumor of the kidney. Cancer Genet Cytogenet 2005;163:130-137.
14. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007;39:347-351.
15. Macconaill LE, Garraway LA. Clinical implications of the cancer genome. J Clin Oncol 2010;28:5219-5228.
16. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 2009;4:e7887.
17. Dias-Santagata D, Lam Q, Vernovsky K, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: Diagnostic and therapeutic implications. PLoS ONE 2011;6:e17948.
18. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010;116:1919-1923.
19. Grill J, Puget S, Andreiuolo F, et al. Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer 2012;58:489-491.
20. Rivera M, Ricarte-Filho J, Knauf J, et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs. infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 2010;23:1191-1200.
21. Horton TM, Berg SL. Educational paper. The development of new therapies for pediatric oncology. Eur J Pediatr 2011;170:555-559.
22. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
23. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004;364:1127-1134.
24. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-1172.
25. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.